Infectious Disease: CARG-201

  • Functional cure for chronic HBV patients
  • Enables robust expression and secretion of HBV middle S and core antigens in vitro
  • Induces broad immune responses
  • Results in reduction HBV marker surface antigens by more than 2 logs in AAV model
  • Eliminates virus as monotherapy or in combination with standard antiviral therapy
  • Pre-IND meeting with the FDA held in 2019
  • Upon successful financing IND filing will be submitted in Q1, 2024
  • IND is planned to be filed with the FDA by the end of 2023
CaroGen Corporation CaroGen Corporation (203) 815-5782